89BIO, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.93 USD | +2.06% |
|
+8.00% | -20.23% |
| 17/04 | 89bio, Inc. Appoints Martin Babler to Its Board of Directors | CI |
| 03/04 | 89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing | MT |
Chart calendar 89bio, Inc.
d7f5923cd37a0ce5f946.U4D6pUAcqmY3vEkwYwJe7qjZBwRhRYha_6GV0P1gyvA.ZufPzhVI9QxF8T9JD3A32uK9VTUrcu8omZPQqYlWv6NntriTJnntKm_dJg~01e3ddf6b0949eea77bcf8c4b792f21d
Upcoming events on 89bio, Inc.
Past events on 89bio, Inc.
| 12/03/2024 11:10 pm | Leerink Partners Global Biopharma Conference - Fireside Chat |
| 01/03/2024 02:35 am | Q4 2023 Earnings Release |
| 13/02/2024 11:50 pm | Oppenheimer Healthcare Life Sciences Conference |
| 28/11/2023 07:15 pm | Evercore ISI HealthCONx Conference |
| 09/11/2023 02:31 am | Q3 2023 Earnings Release |
| 24/10/2023 09:00 pm | H.C. Wainwright NASH Investor Conference - Fireside Chat |
| 26/09/2023 09:10 pm | Cantor Global Healthcare Conference |
| 11/09/2023 04:30 pm | H.C. Wainwright Global Investment Conference |
| 10/08/2023 01:31 am | Q2 2023 Earnings Release |
| 24/06/2023 03:30 pm | European Association for the Study of the Liver Congress - Abstract Number: LBO-05 |
| 24/06/2023 12:30 pm | European Association for the Study of the Liver Congress - Abstract Number: SAT-243 |
| 05/06/2023 09:30 pm | Annual General Meeting |
| 17/05/2023 06:00 pm | RBC Global Healthcare Conference - Fireside Chat |
| 10/05/2023 03:05 am | Bank of America Healthcare Conference |
| 05/05/2023 01:35 am | Q1 2023 Earnings Release |
| 22/03/2023 05:30 pm | ENLIVEN Phase 2 Trial Results Call |
| 10/03/2023 06:30 pm | Q4 2022 Earnings Release |
| 05/03/2023 12:15 am | American College of Cardiology Scientific Conference - Poster Number: 184 |
| 15/02/2023 10:30 pm | SVB Securities Global Biopharma Conference |
| 11/11/2022 02:35 am | Q3 2022 Earnings Release |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,94 |
|
EBITDA Million USD | Released Forecast Spread | -26,6 -30,0 11.24% | -49,3 -55,5 11.23% | -89,7 -90,1 0.48% | -102 -119 14.34% | -151 -149 -1.57% | -222 |
|
EBIT Million USD | Released Forecast Spread | -26,6 -27,3 2.56% | -49,4 -53,3 7.4% | -89,7 -91,1 1.54% | -102 -108 5.33% | -151 -152 0.46% | -208 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -57,2 -49,6 -15.33% | -49,6 -53,1 6.58% | -90,3 -91,2 1.03% | -102 -107 4.48% | -138 -142 2.73% | -191 |
|
Net income Million USD | Released Forecast Spread | -57,4 -49,5 -16% | -49,5 -53,7 7.84% | -90,1 -91,3 1.33% | -102 -109 6.2% | -142 -143 0.42% | -194 |
|
EPS USD | Released Forecast Spread | -24,5 -14,5 -69.48% | -3,08 -3,10 0.69% | -4,48 -4,47 -0.17% | -2,93 -2,72 -7.55% | -2,00 -2,03 1.71% | -2,21 |
| Announcement Date | 18/03/20 | 24/03/21 | 24/03/22 | 10/03/23 | 29/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 0,00 | 0,00 | 0,63 | 0,63 | |
|
EBITDA Million USD | Released Forecast Spread | -24,7 -28,1 12.14% | -39,3 -44,1 10.79% | ||||||||||||
|
EBIT Million USD | Released Forecast Spread | -26,2 -27,6 5.07% | -25,1 -26,2 4.2% | -24,7 -27,0 8.47% | -27,0 -29,7 9.04% | -25,4 -31,1 18.5% | -28,5 -28,5 -0.04% | -42,1 -30,9 -36.51% | -39,3 -41,3 4.66% | -41,2 -41,2 0.01% | -45,7 | -50,5 | -54,9 | -60,2 | -59,8 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -26,4 -27,4 3.47% | -25,6 -26,1 2.11% | -25,1 -27,0 7.32% | -26,8 -28,1 4.64% | -24,6 -29,4 16.29% | -28,8 -27,6 -4.29% | -38,4 -30,4 -26.42% | -34,7 -39,1 11.11% | -36,4 -38,4 5.2% | -41,5 | -46,0 | -51,4 | -57,5 | -55,9 |
|
Net income Million USD | Released Forecast Spread | -63,8 -27,5 -131.94% | -25,6 -26,3 2.72% | -25,1 -27,0 7.32% | -26,8 -29,9 10.35% | -24,6 -31,3 21.47% | -28,8 -28,7 -0.64% | -38,4 -30,4 -26.26% | -34,7 -39,2 11.39% | -40,2 -38,4 -4.91% | -41,8 | -46,9 | -51,9 | -57,4 | -55,9 |
|
EPS USD | Released Forecast Spread | -1,30 -1,29 -0.87% | -1,26 -1,29 2.2% | -1,23 -1,05 -16.96% | -0,57 -0,83 31.68% | -0,48 -0,70 31.15% | -0,54 -0,51 -6.93% | -0,52 -0,42 -25.3% | -0,45 -0,51 12.2% | -0,50 -0,50 0.09% | -0,47 | -0,52 | -0,58 | -0,63 | -0,59 |
| Announcement Date | 24/03/22 | 11/05/22 | 11/08/22 | 10/11/22 | 10/03/23 | 08/05/23 | 09/08/23 | 09/11/23 | 29/02/24 | - | - | - | - | - |
| Today 01:31 am | ASCENDIS PHARMA A/S: Q1 2024 Earnings Release |
| 06/05/2024 | FRAZIER LIFESCIENCES ACQUISITION CORPORATION: Q1 2024 Earnings Release (Projected) |
| 06/05/2024 | KRYSTAL BIOTECH, INC.: Q1 2024 Earnings Release |
| 06/05/2024 | MERUS N.V.: Q1 2024 Earnings Release (Projected) |
| 06/05/2024 | VAXCYTE, INC.: Q1 2024 Earnings Release (Projected) |
| 06/05/2024 | INHIBRX, INC.: Q1 2024 Earnings Release (Projected) |
| 06/05/2024 | BIONTECH SE: Q1 2024 Earnings Release |
| 06/05/2024 04:30 pm | BIOCRYST PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 07/05/2024 01:31 am | VERTEX PHARMACEUTICALS INCORPORATED: Q1 2024 Earnings Release |
| 07/05/2024 | COGENT BIOSCIENCES, INC.: Q1 2024 Earnings Release (Projected) |
Past sector events for 89bio, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ETNB Stock
- Calendar 89bio, Inc.
